

eTable 2 Prevalence of ordinal and binary outcomes for perimenstrual and non-perimenstrual attacks for women with MRM versus non-MRM with corresponding results of mixed effects models

	MRM				Non-MRM			
	Perimenstrual migraine days (n=1724)	Non-perimenstrual migraine days (n=3914)	Adjusted odds ratio 95%CI	Adjusted p-value	Perimenstrual migraine days (n=440)	Non-perimenstrual migraine days (n=2077)	Adjusted odds ratio 95%CI	Adjusted p-value
Photophobia	84.5	79.9	1.3 (1.1-1.4)	<0.001	84.1	81.9	1.2 (0.9-1.5)	0.16
Phonophobia	80.5	75.6	1.2 (1.1-1.4)	0.002	80.9	78.1	1.2 (1.0-1.5)	0.10
Nausea	61.1	58.6	1.0 (0.9-1.2)	0.54	67.7	62.2	0.9 (0.7-1.1)	0.36
Vomiting	7.5	7.5	0.9 (0.7-1.2)	0.49	5.5	7.7	0.7 (0.4-1.1)	0.12
Aura symptoms	7.0	9.7	0.7 (0.5-1.0)	0.03	6.8	11.1	0.6 (0.3-1.3)	0.19
Use of analgesics	45.5	39.5	1.2 (1.0-1.4)	0.04	43.9	49.7	1.1 (0.8-1.5)	0.66
Use of triptans	58.6	54.8	1.2 (1.1-1.5)	0.01	37.3	39.3	1.1 (0.8-1.6)	0.58
2 hour headache response	62.3	64.0	0.9 (0.8-1.1)	0.35	56.7	61.4	0.9 (0.6-1.3)	0.46
2 hour pain-free response	30.6	31.5	1.0 (0.8-1.2)	0.69	25.6	27.2	1.0 (0.6-1.5)	0.90
Recurrence < 24 hours	19.0	14.8	2.7 (2.1-3.3)	<0.001	15.2	13.8	1.8 (1.1-3.1)	0.02
Recurrence < 48 hours	19.1	16.3	3.1 (2.6-3.7)	<0.001	20.7	15.8	2.3 (1.4-3.6)	<0.001

The associated symptoms photophobia, phonophobia, nausea and vomiting were rated on a ordinal scale (no-mild-moderate-severe), all other outcomes presented in the table are rated on a binary scale (no-yes). To obtain frequency numbers on associated symptoms, a comparison was made

between negative replies and positive replies (i.e. mild, moderate or severe were rated as yes). Odds ratios for associated symptoms were calculated based on the ordinal results with ordinal logistic mixed effects models and for all other outcomes with logistic mixed effects models, adjusted for chronic migraine, medication overuse and the use of combined oral contraceptives. Analgesics use was additionally corrected for use because of menstrual pain. Prevalence of 2-hour responses are calculated based on migraine days with triptan intake (respectively n=1011, n=2143, n=164 and n=816 days). Recurrence is calculated based on days with triptan intake including respectively 24 hours and 48 hours.